ClinicalTrials.gg
CompletedNCT01735201Updated Nov 18, 2019Results posted

AGN-199201 for the Treatment of Erythema With Rosacea

A Phase 2 interventional study of AGN-199201 Dose A and AGN-199201 Dose B in Rosacea and Erythema, sponsored by Allergan. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-18.

Sponsored by Allergan (part of AbbVie) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
357
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 145 studies in Rosacea with a site in United States — 8 open to participants now, 9 under way, none of them phase 3. Rosacea · United States.

Enrollment
29th of 137
357 · median 78
Started
2012
with 10 others
Phase 2
35 of 145
4 open now
Registered
48th of 145
by date
Lead sponsor
7 of 145
Allergan

Among the 145 studies in Rosacea with a site in United States, this one is the 29th largest by enrollment of the 137 interventional ones that give a count, is one of 11 that started in 2012, is one of 35 in phase 2, and was the 48th registered.

Rosacea

233 studies on the registry are indexed under Rosacea; 23 are open to participants now.

Browse Rosacea studies →

Open to participants now

8 of the 145 studies in Rosacea with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 17 Rosacea studies recruiting now, 9 (53%) set no upper age limit and 7 (41%) stop at 75 or younger; 1 takes children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 145 studies in Rosacea with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the safety and efficacy of 3 doses of AGN-199201 once and twice daily compared to vehicle for the treatment of moderate to severe facial erythema associated with rosacea.

03

Conditions studied

  • Rosacea
  • Erythema

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Redness of the skin caused by rosacea

Exclusion criteria

Exclusion Criteria:

  • ≥3 inflammatory lesions
  • Laser light-source or other energy based therapy in the last 6 months
  • Any prescription or over the counter product for the treatment of acne or rosacea in the last 14 days
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
357 participants (actual)

Study arms

  • Experimental
    AGN-199201 Dose A Once Daily

    AGN-199201 Dose A applied once daily to the face for 28 days.

    Drug: AGN-199201 Dose A

  • Experimental
    AGN-199201 Dose B Once Daily

    AGN-199201 Dose B applied once daily to the face for 28 days.

    Drug: AGN-199201 Dose B

  • Experimental
    AGN-199201 Dose C Once Daily

    AGN-199201 Dose C applied once daily to the face for 28 days.

    Drug: AGN-199201 Dose C

  • Placebo comparator
    AGN-199201 Vehicle Once Daily

    AGN-199201 Vehicle applied once daily to the face for 28 days.

    Drug: AGN-199201 Vehicle

  • Experimental
    AGN-199201 Dose A Twice Daily

    AGN-199201 Dose A applied twice daily to the face for 28 days.

    Drug: AGN-199201 Dose A

  • Experimental
    AGN-199201 Dose B Twice Daily

    AGN-199201 Dose B applied twice daily to the face for 28 days.

    Drug: AGN-199201 Dose B

  • Experimental
    AGN-199201 Dose C Twice Daily

    AGN-199201 Dose C applied twice daily to the face for 28 days.

    Drug: AGN-199201 Dose C

  • Placebo comparator
    AGN-199201 Vehicle Twice Daily

    AGN-199201 Vehicle applied twice daily to the face for 28 days.

    Drug: AGN-199201 Vehicle

Interventions

  • AGN-199201 Dose A applied once or twice daily to the face for 28 days.

  • AGN-199201 Dose B applied once or twice daily to the face for 28 days.

  • AGN-199201 Dose C applied once or twice daily to the face for 28 days.

  • DrugAGN-199201 Vehicle

    AGN-199201 Vehicle applied once or twice daily to the face for 28 days.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With at Least a 2-Grade Decrease From Baseline on Both Clinician Erythema Assessment (CEA) and Subject Self-Assessment (SSA)

    Percentage of participants with at least a 2-grade decrease from Baseline (Improvement) in the CEA score and at least a 2-grade decrease from Baseline (Improvement) in the SSA score were assessed on Day 28 hours 2 to 12. The investigator evaluated the severity of the participant's erythema (redness of the skin) as measured by the CEA using a 5-point scale where 0=clear skin with no signs of erythema; 1=almost clear of erythema, slight redness; 2=mild erythema, definite redness; 3=moderate erythema, marked redness and 4=severe erythema, fiery redness. The participant assessed the severity of their erythema as measured by the SSA using a 5-point scale where 0=clear of unwanted redness; 1=nearly clear of unwanted redness; 2=somewhat more redness than I prefer; 3=more redness than I prefer and 4=completely unacceptable redness.

    Time frame: Baseline, Day 28-hours 2 to 12

Secondary outcomes

  1. Percentage of Participants With at Least a 2-Grade Decrease From Baseline on Both CEA and SSA at 0.5 Hour Post-Dose on Day 28

    Percentage of participants with at least a 2-grade decrease from Baseline (Improvement) in the CEA score and at least a 2-grade decrease from Baseline (Improvement) in the SSA score were assessed at 0.5 hour post-dose on Day 28. The investigator evaluated the severity of the participant's erythema (redness of the skin) as measured by the CEA using a 5-point scale where 0=clear skin with no signs of erythema; 1=almost clear of erythema, slight redness; 2=mild erythema, definite redness; 3=moderate erythema, marked redness and 4=severe erythema, fiery redness. The participant assessed the severity of their erythema as measured by the SSA using a 5-point scale where 0=clear of unwanted redness; 1=nearly clear of unwanted redness; 2=somewhat more redness than I prefer; 3=more redness than I prefer and 4=completely unacceptable redness.

    Time frame: Baseline, Day 28-hour 0.5

  2. Percentage of Participants With at Least a 2-Grade Decrease From Baseline on Both CEA and SSA at 1 Hour Post-Dose on Day 28

    Percentage of participants with at least a 2-grade decrease from Baseline (Improvement) in the CEA score and at least a 2-grade decrease from Baseline (Improvement) in the SSA score were assessed at 1 hour post-dose on Day 28. The investigator evaluated the severity of the participant's erythema (redness of the skin) as measured by the CEA using a 5-point scale where 0=clear skin with no signs of erythema; 1=almost clear of erythema, slight redness; 2=mild erythema, definite redness; 3=moderate erythema, marked redness and 4=severe erythema, fiery redness. The participant assessed the severity of their erythema as measured by the SSA using a 5-point scale where 0=clear of unwanted redness; 1=nearly clear of unwanted redness; 2=somewhat more redness than I prefer; 3=more redness than I prefer and 4=completely unacceptable redness.

    Time frame: Baseline, Day 28-hour 1

07

Results

Posted May 30, 2014

Participant flow

Participant flow — Overall Study
MilestoneAGN-199201 Dose A Once DailyAGN-199201 Dose B Once DailyAGN-199201 Dose C Once DailyAGN-199201 Vehicle Once DailyAGN-199201 Dose A Twice DailyAGN-199201 Dose B Twice DailyAGN-199201 Dose C Twice DailyAGN-199201 Vehicle Twice Daily
Started4544444445454544
Completed4243444244404242
Not completed31021532
Withdrew: Adverse event11011321
Withdrew: Personal reasons10000000
Withdrew: Protocol violation10000000
Withdrew: Other miscellaneous reasons00010211

Outcome measures

PrimaryPercentage of Participants With at Least a 2-Grade Decrease From Baseline on Both Clinician Erythema Assessment (CEA) and Subject Self-Assessment (SSA)

Percentage of participants with at least a 2-grade decrease from Baseline (Improvement) in the CEA score and at least a 2-grade decrease from Baseline (Improvement) in the SSA score were assessed on Day 28 hours 2 to 12. The investigator evaluated the severity of the participant's erythema (redness of the skin) as measured by the CEA using a 5-point scale where 0=clear skin with no signs of erythema; 1=almost clear of erythema, slight redness; 2=mild erythema, definite redness; 3=moderate erythema, marked redness and 4=severe erythema, fiery redness. The participant assessed the severity of their erythema as measured by the SSA using a 5-point scale where 0=clear of unwanted redness; 1=nearly clear of unwanted redness; 2=somewhat more redness than I prefer; 3=more redness than I prefer and 4=completely unacceptable redness.

Time frame:
Baseline, Day 28-hours 2 to 12
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least a 2-Grade Decrease From Baseline on Both Clinician Erythema Assessment (CEA) and Subject Self-Assessment (SSA)
Percentage of participantsAGN-199201 Dose A Once DailyAGN-199201 Dose B Once DailyAGN-199201 Dose C Once DailyAGN-199201 Vehicle Once DailyAGN-199201 Dose A Twice DailyAGN-199201 Dose B Twice DailyAGN-199201 Dose C Twice DailyAGN-199201 Vehicle Twice Daily
Hour 213.320.522.76.88.917.815.66.8
Hour 417.831.827.34.511.120.022.26.8
Hour 617.822.713.64.511.113.324.44.5
Hour 815.620.520.54.58.920.020.02.3
Hour 1017.820.513.64.513.315.626.72.3
Hour 1213.313.613.62.313.311.115.64.5
SecondaryPercentage of Participants With at Least a 2-Grade Decrease From Baseline on Both CEA and SSA at 0.5 Hour Post-Dose on Day 28

Percentage of participants with at least a 2-grade decrease from Baseline (Improvement) in the CEA score and at least a 2-grade decrease from Baseline (Improvement) in the SSA score were assessed at 0.5 hour post-dose on Day 28. The investigator evaluated the severity of the participant's erythema (redness of the skin) as measured by the CEA using a 5-point scale where 0=clear skin with no signs of erythema; 1=almost clear of erythema, slight redness; 2=mild erythema, definite redness; 3=moderate erythema, marked redness and 4=severe erythema, fiery redness. The participant assessed the severity of their erythema as measured by the SSA using a 5-point scale where 0=clear of unwanted redness; 1=nearly clear of unwanted redness; 2=somewhat more redness than I prefer; 3=more redness than I prefer and 4=completely unacceptable redness.

Time frame:
Baseline, Day 28-hour 0.5
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least a 2-Grade Decrease From Baseline on Both CEA and SSA at 0.5 Hour Post-Dose on Day 28
Percentage of participantsAGN-199201 Dose A Once DailyAGN-199201 Dose B Once DailyAGN-199201 Dose C Once DailyAGN-199201 Vehicle Once DailyAGN-199201 Dose A Twice DailyAGN-199201 Dose B Twice DailyAGN-199201 Dose C Twice DailyAGN-199201 Vehicle Twice Daily
Percentage of Participants With at Least a 2-Grade Decrease From Baseline on Both CEA and SSA at 0.5 Hour Post-Dose on Day 286.711.46.84.56.76.76.72.3
SecondaryPercentage of Participants With at Least a 2-Grade Decrease From Baseline on Both CEA and SSA at 1 Hour Post-Dose on Day 28

Percentage of participants with at least a 2-grade decrease from Baseline (Improvement) in the CEA score and at least a 2-grade decrease from Baseline (Improvement) in the SSA score were assessed at 1 hour post-dose on Day 28. The investigator evaluated the severity of the participant's erythema (redness of the skin) as measured by the CEA using a 5-point scale where 0=clear skin with no signs of erythema; 1=almost clear of erythema, slight redness; 2=mild erythema, definite redness; 3=moderate erythema, marked redness and 4=severe erythema, fiery redness. The participant assessed the severity of their erythema as measured by the SSA using a 5-point scale where 0=clear of unwanted redness; 1=nearly clear of unwanted redness; 2=somewhat more redness than I prefer; 3=more redness than I prefer and 4=completely unacceptable redness.

Time frame:
Baseline, Day 28-hour 1
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least a 2-Grade Decrease From Baseline on Both CEA and SSA at 1 Hour Post-Dose on Day 28
Percentage of participantsAGN-199201 Dose A Once DailyAGN-199201 Dose B Once DailyAGN-199201 Dose C Once DailyAGN-199201 Vehicle Once DailyAGN-199201 Dose A Twice DailyAGN-199201 Dose B Twice DailyAGN-199201 Dose C Twice DailyAGN-199201 Vehicle Twice Daily
Percentage of Participants With at Least a 2-Grade Decrease From Baseline on Both CEA and SSA at 1 Hour Post-Dose on Day 2811.113.618.22.36.711.18.92.3

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AGN-199201 Dose A Once Daily—0/45 (0%)5/45 (11.1%)
AGN-199201 Dose B Once Daily—1/44 (2.3%)5/44 (11.4%)
AGN-199201 Dose C Once Daily—0/44 (0%)1/44 (2.3%)
AGN-199201 Vehicle Once Daily—1/44 (2.3%)1/44 (2.3%)
AGN-199201 Dose A Twice Daily—0/45 (0%)2/45 (4.4%)
AGN-199201 Dose B Twice Daily—1/45 (2.2%)6/45 (13.3%)
AGN-199201 Dose C Twice Daily—0/45 (0%)7/45 (15.6%)
AGN-199201 Vehicle Twice Daily—0/44 (0%)6/44 (13.6%)
Most frequent serious events
Most frequent serious events
EventAGN-199201 Dose A Once DailyAGN-199201 Dose B Once DailyAGN-199201 Dose C Once DailyAGN-199201 Vehicle Once DailyAGN-199201 Dose A Twice DailyAGN-199201 Dose B Twice DailyAGN-199201 Dose C Twice DailyAGN-199201 Vehicle Twice Daily
Cardiac failure congestiveCardiac disorders0/450/440/441/440/450/450/450/44
Chondrocalcinosis pyrophosphateMusculoskeletal and connective tissue disorders0/451/440/440/440/450/450/450/44
Rotator cuff syndromeMusculoskeletal and connective tissue disorders0/450/440/441/440/450/450/450/44
HypertensionVascular disorders0/450/440/441/440/450/450/450/44
Cerebrovascular accidentNervous system disorders0/450/440/440/440/451/450/450/44
Most frequent other events
Most frequent other events
EventAGN-199201 Dose A Once DailyAGN-199201 Dose B Once DailyAGN-199201 Dose C Once DailyAGN-199201 Vehicle Once DailyAGN-199201 Dose A Twice DailyAGN-199201 Dose B Twice DailyAGN-199201 Dose C Twice DailyAGN-199201 Vehicle Twice Daily
HeadacheNervous system disorders4/451/440/441/441/453/454/453/44
Application site dermatitisGeneral disorders0/453/440/440/441/453/452/450/44
Application site acneGeneral disorders1/451/441/440/440/450/451/453/44

Baseline characteristics

Age, Customized
Age, Customized(Participants)AGN-199201 Dose A Once DailyAGN-199201 Dose B Once DailyAGN-199201 Dose C Once DailyAGN-199201 Vehicle Once DailyAGN-199201 Dose A Twice DailyAGN-199201 Dose B Twice DailyAGN-199201 Dose C Twice DailyAGN-199201 Vehicle Twice DailyTotal
< 45 years141510141611169105
45-64 years3023282426292728215
>= 65 years1666352736
Sex: Female, Male
Sex: Female, Male(Participants)AGN-199201 Dose A Once DailyAGN-199201 Dose B Once DailyAGN-199201 Dose C Once DailyAGN-199201 Vehicle Once DailyAGN-199201 Dose A Twice DailyAGN-199201 Dose B Twice DailyAGN-199201 Dose C Twice DailyAGN-199201 Vehicle Twice DailyTotal
Female3535333841343633285
Male10911641191171
08

Study locations

1 site
  • Austin, Texas, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2012, a primary completion of May 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.

Results were first posted in May 2014, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2012
First posted
Nov 28, 2012
Start
Dec 2012
Primary completionActual
May 2013
CompletionActual
Jun 2013
Results first posted
May 30, 2014
Last update
Nov 18, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01735201
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
Nov 28, 2012
Start date
Dec 2012
Primary completion
May 2013
Completion
Jun 2013
Results posted
May 30, 2014
Last update
Nov 18, 2019

Study contacts

Medical Director
study director · Allergan

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Oxymetazoline

Start the discussion